UNSPSC 51433929: Barnidipine hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C27H29N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LZ6R3AEM1, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-pyrrolidinyl ester, monohydrochloride, (s-(r*,r*))- but more generally known as barnidipine hydrochloride, which bears US NIH Compound Identifier 163733.

UNSPSC 51433929 Barnidipine hydrochloride is a Commodity code covering a specific calcium channel blocker pharmaceutical used primarily in emergency medical services and institutional pharmacy programs. State and local governments procure this product as part of broader advanced life support medication portfolios—typically for fire rescue departments, emergency medical services, and health agency pharmacy benefit programs. The issuing bodies include city purchasing departments serving emergency services, state health and human services commissions managing pharmacy benefit programs, and multistate cooperative purchasing alliances consolidating pharmaceutical procurement across multiple jurisdictions. Work under this code involves supplying compliant pharmaceutical products with certified manufacturing practices, maintaining expiration-date warranties, arranging delivery and replacement logistics, and submitting safety documentation and accessibility compliance reporting.

Recent activity appears concentrated in Florida and Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (response deadline April 8, 2026), a sealed-bid procurement for four specific medication line items including other critical-care agents for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future formal procurement but no current binding solicitation. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with a two-year term effective July 1, 2026, and a 3 percent administrative fee structure. Multistate cooperative vehicles appear active in pharmaceutical procurement, and fire rescue departments represent a consistent user segment for this category.